Maia Biotechnology, INC. (MAIA) — SEC Filings

Q: What are the key financial highlights for Maia Biotechnology, INC.?

Key financial highlights for Maia Biotechnology, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Maia Biotechnology, INC.?

Key executives at Maia Biotechnology, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Maia Biotechnology, INC. stock?

Risk factors for Maia Biotechnology, INC. (MAIA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Maia Biotechnology, INC.?

Forward-looking statements and predictions from Maia Biotechnology, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Maia Biotechnology, INC.. Recent 8-K filing on Apr 8, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Maia Biotechnology, INC. on SEC EDGAR

Overview

Maia Biotechnology, INC. (MAIA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: MAIA Biotechnology, Inc. filed an 8-K on March 31, 2026, reporting other events and financial statements. The filing includes an exhibit (EX-99.1) and interactive data files, indicating updates or disclosures relevant to the company's financial status and operations.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Maia Biotechnology, INC. is neutral.

Filing Type Overview

Maia Biotechnology, INC. (MAIA) has filed 43 8-K, 1 ARS, 1 DEFA14A, 3 10-Q, 1 DEF 14A, 1 10-K with the SEC between Feb 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

8-K Filing — 8-K · Apr 8, 2026
ARS Filing — ARS · Apr 7, 2026
DEFA14A Filing — DEFA14A · Apr 7, 2026
MAIA Biotechnology Files 8-K — 8-K · Mar 31, 2026 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on March 31, 2026, reporting other events and financial statements. The filing includes an exhibit (EX-99.1) and interacti
MAIA Biotechnology Files 8-K — 8-K · Mar 27, 2026 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on March 27, 2026, reporting under Regulation FD and other events. The filing includes financial statements and exhibits,
MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 17, 2025 Risk: medium
On December 16, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securitie
8-K Filing — 8-K · Dec 11, 2025
8-K Filing — 8-K · Dec 10, 2025
MAIA Biotechnology Files 8-K — 8-K · Nov 21, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on November 21, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specif
MAIA Biotechnology Files 8-K — 8-K · Nov 20, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on November 20, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its prin
MAIA Biotech's Losses Widen Amid Soaring R&D, Going Concern Doubts Persist — 10-Q · Nov 7, 2025 Risk: high
MAIA Biotechnology, Inc. reported a net loss of $8,903,189 for the three months ended September 30, 2025, a significant increase from the $2,735,987 net loss in
MAIA Biotechnology Files 8-K Report — 8-K · Oct 27, 2025 Risk: low
On October 27, 2025, MAIA Biotechnology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no
MAIA Biotechnology Files 8-K — 8-K · Oct 24, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on October 24, 2025, reporting other events and financial statements. The filing details the company's incorporation in De
MAIA Biotechnology Files 8-K — 8-K · Oct 23, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on October 23, 2025, reporting events that occurred on October 19, 2025. The filing includes information related to Regula
MAIA Biotechnology Files 8-K: Material Agreement, Equity Sales — 8-K · Oct 14, 2025 Risk: medium
On October 13, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
MAIA Biotechnology Files 8-K — 8-K · Oct 7, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on October 7, 2025, reporting other events and financial statements. The filing does not contain specific details about th
MAIA Biotechnology Files 8-K on Key Agreements and Equity Sales — 8-K · Sep 30, 2025 Risk: medium
MAIA Biotechnology, Inc. filed an 8-K on September 30, 2025, reporting on several events that occurred on September 29, 2025. These include entering into a mate
MAIA Biotechnology Files 8-K — 8-K · Sep 24, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on September 24, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is based in
MAIA Biotechnology Files 8-K on Material Agreement — 8-K · Sep 18, 2025 Risk: medium
On September 18, 2025, MAIA Biotechnology, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equi
MAIA Biotechnology Files 8-K — 8-K · Sep 12, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on September 12, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its pri
MAIA Biotechnology Files 8-K — 8-K · Sep 11, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on September 11, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
MAIA Biotechnology to Acquire Private Company — 8-K · Sep 8, 2025 Risk: medium
MAIA Biotechnology, Inc. announced on September 7, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of a privat
MAIA Biotechnology Files 8-K — 8-K · Aug 13, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on August 13, 2025, reporting other events and financial statements. The filing does not contain specific financial figure
MAIA Biotech Continues Pre-Revenue Phase, Focuses on THIO Clinical Trials — 10-Q · Aug 11, 2025 Risk: high
MAIA Biotechnology, Inc. reported no revenue for the three and six months ended June 30, 2025, and June 30, 2024, consistent with its pre-commercialization stag
MAIA Biotechnology Files 8-K — 8-K · Jul 28, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on July 28, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific d
MAIA Biotechnology Files 8-K — 8-K · Jul 17, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on July 17, 2025, reporting other events and financial statements. The filing does not contain specific details about the
MAIA Biotechnology Files 8-K — 8-K · Jul 9, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on July 9, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing details the company's incorp
MAIA Biotechnology Files 8-K with Key Agreements and Sales — 8-K · Jun 26, 2025 Risk: medium
On June 24, 2025, MAIA Biotechnology, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, reported
MAIA Biotechnology Files 8-K — 8-K · Jun 24, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on June 24, 2025, reporting other events and financial statements. The filing does not contain specific details about the
MAIA Biotechnology Files 8-K — 8-K · Jun 18, 2025 Risk: low
On June 18, 2025, MAIA Biotechnology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating
MAIA Biotechnology Files 8-K on Material Agreement — 8-K · Jun 17, 2025 Risk: medium
On June 17, 2025, MAIA Biotechnology, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity se
MAIA Biotechnology Files 8-K — 8-K · Jun 5, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on June 5, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific de
8-K Filing — 8-K · Jun 2, 2025
MAIA Biotechnology Files 8-K: Material Agreement, Equity Sales — 8-K · May 28, 2025 Risk: medium
On May 27, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
MAIA Biotechnology Files 8-K for Bylaw Amendments — 8-K · May 23, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on May 23, 2025, reporting events as of May 22, 2025. The filing primarily concerns amendments to its articles of incorpor
MAIA Biotechnology Files 8-K — 8-K · May 22, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on May 22, 2025, reporting on matters submitted to a vote of security holders, other events, and financial statements/exhi
MAIA Biotechnology Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: medium
MAIA Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, includi
MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales — 8-K · May 6, 2025 Risk: medium
On May 5, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
8-K Filing — 8-K · Apr 22, 2025
MAIA Biotechnology Files Definitive Proxy Statement — DEF 14A · Apr 8, 2025 Risk: low
MAIA Biotechnology, Inc. filed its definitive proxy statement (DEF 14A) on April 8, 2025, for its annual meeting on May 22, 2025. The filing concerns the solici
MAIA Biotechnology Files 8-K — 8-K · Apr 1, 2025 Risk: low
On April 1, 2025, MAIA Biotechnology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating
MAIA Biotechnology Files 8-K — 8-K · Mar 28, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on March 28, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
MAIA Biotechnology Files 8-K — 8-K · Mar 26, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on March 26, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its princip
MAIA Biotechnology Files 8-K — 8-K · Mar 21, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on March 21, 2025, reporting other events and financial statements. The filing details the company's incorporation in Dela
MAIA Biotechnology Files 2024 10-K Amidst Offerings — 10-K · Mar 21, 2025 Risk: medium
MAIA Biotechnology, Inc. filed its 2024 10-K on March 21, 2025, detailing its operations and financial status for the fiscal year ending December 31, 2024. The
MAIA Biotechnology Files 8-K — 8-K · Mar 19, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on March 19, 2025, reporting other events and financial statements. The filing details the company's incorporation in Dela
MAIA Biotechnology Files 8-K — 8-K · Feb 27, 2025 Risk: low
MAIA Biotechnology, Inc. filed an 8-K on February 27, 2025, reporting other events and financial statements. The filing details the company's corporate structur
MAIA Biotechnology Files 8-K: Material Agreement, Equity Sales — 8-K · Feb 25, 2025 Risk: medium
MAIA Biotechnology, Inc. announced on February 24, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales o
MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 19, 2025 Risk: medium
MAIA Biotechnology, Inc. announced on February 18, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales o
MAIA Biotechnology Files 8-K on Director/Officer Changes — 8-K · Feb 6, 2025 Risk: medium
MAIA Biotechnology, Inc. filed an 8-K on February 6, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and comp

Risk Profile

Risk Assessment: Of MAIA's 43 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 27 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Louie NgarYee
Steven Chaouki
Cristian Luput

Industry Context

The biotechnology industry, particularly in oncology, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like MAIA Biotechnology, Inc. operate in a competitive landscape where innovation is key, but success is contingent on clinical trial outcomes and regulatory approvals. The sector relies heavily on external funding, often through equity offerings, to finance these extensive development processes.

Top Tags

8-K (14) · 8-k (11) · material-agreement (10) · equity-sale (10) · regulatory-filing (9) · filing (8) · financials (6) · corporate-update (4) · sec-filing (4) · corporate-filing (4)

Key Numbers

SEC Accession Number: 0001493152-26-013879 — Unique identifier for this specific SEC filing
CIK: 0001878313 — Central Index Key for MAIA Biotechnology, Inc.
8-K Document Size: 38779 — Size of the main 8-K filing in bytes.
EX-99.1 Document Size: 1106 — Size of Exhibit 99.1 in bytes.
SEC File Number: 001-41455 — Identifies the company's filing with the SEC.
Net loss for Q3 2025: $8,903,189 — Increased from $2,735,987 in Q3 2024
Net loss for nine months ended Sep 30, 2025: $18,767,410 — Improved from $19,682,718 in the prior year period
Research and development expenses for Q3 2025: $6,357,290 — Increased from $2,667,170 in Q3 2024, a 138% increase
Cash as of Sep 30, 2025: $10,891,736 — Increased from $9,601,298 at Dec 31, 2024
Accumulated deficit as of Sep 30, 2025: $106,002,244 — Indicates significant historical losses
Working capital as of Sep 30, 2025: $1,760,992 — Low working capital contributes to going concern doubt
Shares of common stock outstanding as of Nov 7, 2025: 37,032,307 — Reflects recent share issuances
IRS Employer Identification No.: 83-1495913 — Tax identification number for the company.
Filing Date: 20250918 — The report was filed on this date.
Revenue for Q2 2025: $0 — Indicates pre-commercialization stage and reliance on external funding.

Frequently Asked Questions

What are the latest SEC filings for Maia Biotechnology, INC. (MAIA)?

Maia Biotechnology, INC. has 50 recent SEC filings from Feb 2025 to Apr 2026, including 43 8-K, 3 10-Q, 1 ARS. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of MAIA filings?

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant sentiment is neutral.

Where can I find Maia Biotechnology, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Maia Biotechnology, INC. (MAIA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Maia Biotechnology, INC.?

Key financial highlights from Maia Biotechnology, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for MAIA?

The investment thesis for MAIA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Maia Biotechnology, INC.?

Key executives identified across Maia Biotechnology, INC.'s filings include Louie NgarYee, Steven Chaouki, Cristian Luput.

What are the main risk factors for Maia Biotechnology, INC. stock?

Of MAIA's 43 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 27 low-risk.

What are recent predictions and forward guidance from Maia Biotechnology, INC.?

Forward guidance and predictions for Maia Biotechnology, INC. are extracted from SEC filings as they are enriched.